The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas

Exclusion Criteria

• •Participants cannot participate in this study if they meet any of the following conditions:
• •1. Subjects participated in clinical studies of other drugs or medical devices within 3 months before screening.
• •2. Known to be allergic to temozolomide capsules;
• •3. Have been diagnosed with pituitary carcinoma or have other malignant tumors;
• •4. Have received radiation therapy for Sella region;
• •5. Those with severe acute and chronic diseases in various systems, whose conditions have not been effectively controlled, and whose conditions are unstable, including but not limited to:
• •1. Patients with cardiac insufficiency (NYHA cardiac function grade ≥ 2), patients with severe heart disease such as cardiomyopathy, coronary heart disease, severe arrhythmia, etc. that are not effectively controlled;
• •2. Severe active infections,
• •3. Uncontrollable diabetes, hypertension / hypotension, cerebrovascular disease, gastric ulcer, respiratory disease, active autoimmune disease, etc .;
• •4. History of any other diseases that the researcher judges to be unsuitable for the trial, etc .;
• •6. For hepatic and renal insufficiency, hematological indicators: total bilirubin\> 1.5 × ULN, ALT, AST\> 2.5 × ULN; serum creatinine\> 2 × ULN;
• •7. Those with a neutrophil count of less than 1.5 × 109 / L, or a platelet count of less than 100 × 109 / L, or an HGB of less than 90g / L;
• •8. Hepatitis B surface antigen, anti-HCV, anti-HIV or syphilis antibody positive;
• •9. Those who need to take valproic acid and drugs that can cause bone marrow depression during the application or research period;
• •10. pregnant or lactating women or those planning to become pregnant;
• •11. People with history of difficulty in drawing blood;
• •12. People with a history of bleeding disorders;
• •13. Subjects had a history of drug use or smoking and alcohol abuse within 6 months before enrollment;
• •14. Researchers do not consider it appropriate to participate in the trial.